lifestyle.mmminimal.com

Author: ReviR Therapeutics (Shenzhen) Limited

ReviR Therapeutics Receives Strategic Investment from CureCMT to Advance a First-of-its-Kind Precision Medicine Platform for CMT

April 21, 2026
ReviR Therapeutics Announces First Participant Dosed in Phase 1 Study and Secures CDE Clearance for Two Orphan Indications in China, Supporting Future U.S. Expansion Strategy

March 2, 2026
ReviR Therapeutics Receives $4.6 Million CIRM Grant to Advance Huntington’s Disease Treatment and Announces Key Development Milestone

November 22, 2025